Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: TNBC - Triple-Negative Breast Cancer
Interventions: DRUG: Eribulin|DRUG: anti-PD-1 antibody
Sponsor: Beijing 302 Hospital